相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Recent Advances on the s-Triazine Scaffold with Emphasis on Synthesis, Structure-Activity and Pharmacological Aspects: A Concise Review
Ab Majeed Ganai et al.
CHEMISTRYSELECT (2021)
New approaches and procedures for cancer treatment: Current perspectives
Dejene Tolossa Debela et al.
SAGE OPEN MEDICINE (2021)
Discovery of 3,6-disubstituted pyridazines as a novel class of anticancer agents targeting cyclin-dependent kinase 2: synthesis, biological evaluation and in silico insights
Ahmed Sabt et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2020)
Properties of FDA-approved small molecule protein kinase inhibitors
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2019)
Synthesis and bioevaluation of 6-chloropyridazin-3-yl hydrazones and 6-chloro-3-substituted-[1,2,4]triazolo[4,3-b] pyridazines as cytotoxic agents
Mamta et al.
BIOORGANIC CHEMISTRY (2019)
New Quinoline-Based Heterocycles as Anticancer Agents Targeting Bcl-2
Rania Hamdy et al.
MOLECULES (2019)
Analyses of repeated failures in cancer therapy for solid tumors: poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs
Hiroshi Maeda et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2018)
Structurally Diverse Mitochondrial Branched Chain Aminotransferase (BCATm) Leads with Varying Binding Modes Identified by Fragment Screening
Jennifer A. Borthwick et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Synthesis and Bioevaluation of 3,6-Diaryl-[1,2,4]ltriazolo[4,3-b]Pyridazines as Antitubulin Agents
Qile Xu et al.
ACS MEDICINAL CHEMISTRY LETTERS (2016)
Discovery of Potent and Selective 8-Fluorotriazolopyridine c-Met Inhibitors
Emily A. Peterson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Kinase domain inhibition of leucine rich repeat kinase 2 (LRRK2) using a [1,2,4]triazolo[4,3-b]pyridazine scaffold
Paul Galatsis et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2014)
Design, Synthesis, Crystallographic Studies, and Preliminary Biological Appraisal of New Substituted Triazolo[4,3-b]pyridazin-8-amine Derivatives as Tankyrase Inhibitors
Paride Liscio et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Triazolopyridazine LRRK2 kinase inhibitors
Maurizio Franzini et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Lessons from (S)-6-(1-(6-(1-Methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an Inhibitor of Receptor Tyrosine Kinase c-Met with High Protein Kinase Selectivity but Broad Phosphodiesterase Family Inhibition Leading to Myocardial Degeneration in Rats
J. Jean Cui et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Synthesis and anticonvulsant activity of a new 6-alkoxy-[1,2,4]triazolo[4,3-b]pyridazine
Li-Ping Guan et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2010)
Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors
Amanda P. Skoumbourdis et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Targeting cancer with small molecule kinase inhibitors
Jianming Zhang et al.
NATURE REVIEWS CANCER (2009)
7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine:: A functionally selective γ-aminobutyric acidA (GABAA) α2/α3-subtype selective agonist that exhibits potent anxiolytic activity but is not sedating in animal models
RW Carling et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Antibacterial and antifungal activities of new pyrazolo[3,4-d]pyridazin derivatives
E Akbas et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2005)
Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: An update
C Soldani et al.
APOPTOSIS (2002)
Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139
EP Rogakou et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
分享论文
